Result of evaluation of DRP for TKI drug from Big Pharma available third week of January 2018



Company News

Hoersholm, Denmark, December 14, 2017 – MPI announces result of the evaluation of DRP prediction of patient response to the undisclosed small molecule, kinase inhibitor (TKI) in-licensed from Novartis Pharma AG (Basel, Switzerland) by Oncology Venture, to be available and disclosed third week of January 2018. The analysis of the tumor tissue is done by a third party on behalf of Novartis and the evaluation of the DRP’s ability to predict which patients had positive outcome of the treatment is done by Novartis.

In July 2017 Oncology Venture entered into an agreement with Novartis providing Oncology Venture with an option right to execute an exclusive license to develop and commercialize an undisclosed small molecule, multi tyrosine kinase inhibitor in clinical development. The molecule has been explored in multiple clinical trials in several cancer indications including a variety of solid tumors. 

“I look very much forward to receive the data. If the DRP is confirmed in this study of Novartis TKI this will be of major importance to MPIs DRP technology platform” said Peter Buhl Jensen, M.D., CEO of Medical Prognosis Institute

About MPI’s Drug Response Predictor – DRP®
MPI’s DRP® is a tool for developing tumor-derived genetic signatures to predict which cancer patients are high likely to respond to a given anti-cancer product. The DRP® has been tested in 37 trials, where 29 trials showed that drug-specific DRP® Biomarkers could predict which patients responded well to the treatment. The DRP® platform has amongst others been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP® method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given anti-cancer drug.  In addition to this, the individual genetic patterns of patients can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of patients with a high likelihood of response to the drug. DRP® builds on comparison between sensitive and resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. The DRP® is a Big Data tool based on messenger RNA.
The DRP® platform can be used in all cancer types, and has been patented for more than 60 anti-cancer drugs in the US.

About MPI
Medical Prognosis is a publicly traded international company specialized in improving cancer patients lives by developing Personalized Medicine using its unique DRP® technology. MPI’s exceptional opportunity to personalize cancer treatment – begins with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI’s DRP® tool has shown its ability to separate patients who benefit and who do not benefit from a specific cancer treatment. This has been shown in as many as 29 out of 37 trials, and covers more than 80 anti-cancer treatments in a wide range of cancer indications. MPI has built a significant large database with over 1,100 screened breast cancer patients and is building up a database in Multiple Myeloma to be followed by Prostate cancer in collaboration with oncologists and hematologists throughout Denmark.

About Oncology Venture Sweden AB
Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has an exclusive license to use the Drug Response Predictor (DRP®) technology in order to significantly increase the probability of success in clinical trials. DRP® has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients’ tumors’ genes are screened first with DRP® and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient.
The current product portfolio: LiPlaCis® for Breast Cancer in collaboration with Cadila Pharmaceuticals, Irofulven developed from a fungus for prostate cancer and APO010 – an immuno-oncology product for Multiple Myeloma. Oncology Venture has spun out two companies in Special Purpose Vehicles: 2X Oncology Inc. a US based company focusing on Precision medicine for women’s cancers with a pipeline of three promising phase 2 product candidates and Danish OV-SPV 2 will test and potentially develop the Novartis small molecule kinase inhibitor.

For further information, please contact:
CEO, Peter Buhl Jensen, MD, PhD                                                           Ulla Hald Buhl, IR & Communication
E-mail: pbj@medical-prognosis.com                                                             E-mail: uhb@medical-prognosis.com
Telephone: +45 21 60 89 22                                                                          Telephone +45 21 70 10 49